2,889
Views
29
CrossRef citations to date
0
Altmetric
Original Research

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors

, , , , &
Article: e1168557 | Received 18 Feb 2016, Accepted 14 Mar 2016, Published online: 15 Jun 2016

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.